Tarsus Pharmaceuticals (TARS) Free Cash Flow (2019 - 2026)

Tarsus Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$30.5 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 47.27% year-over-year to -$30.5 million; the TTM figure through Mar 2026 stood at -$32.1 million (up 52.46% YoY), while the FY2025 annual figure was -$22.3 million, up 73.63% from the prior year.
• Free Cash Flow was -$30.5 million for Q1 2026 at Tarsus Pharmaceuticals, down from $13.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $15.1 million in Q3 2025 to a low of -$38.0 million in Q4 2023.
• Historically, Free Cash Flow has averaged -$17.9 million across 5 years, with a median of -$20.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 492.09% in 2023, then soared 248.86% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$10.5 million in 2022, then slumped by 261.04% to -$38.0 million in 2023, then soared by 41.39% to -$22.3 million in 2024, then soared by 158.29% to $13.0 million in 2025, then plunged by 334.89% to -$30.5 million in 2026.
• The last three Free Cash Flow figures came in at -$30.5 million (Q1 2026), $13.0 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.